ARTICLE | Company News
CrystalGenomics, AstraZeneca deal
January 25, 2010 8:00 AM UTC
CrystalGenomics will use its structure-based drug discovery technologies to identify compounds against an undisclosed antibacterial target from AstraZeneca. The pharma will own rights to IP developed ...